Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Treatment patterns for metastatic colorectal cancer in Spain.

Aranda E, Polo E, Camps C, Carrato A, Díaz-Rubio E, Guillem V, López R, Antón A.

Clin Transl Oncol. 2020 Jan 23. doi: 10.1007/s12094-019-02279-5. [Epub ahead of print]

PMID:
31974819
2.

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.

Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E.

ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019. Erratum in: ESMO Open. 2020 Jan;5(1):.

3.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group.

JAMA Netw Open. 2019 Sep 4;2(9):e1911750. doi: 10.1001/jamanetworkopen.2019.11750.

4.

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.

Camps Herrero C, Antón Torres A, Cruz-Hernández JJ, Carrato A, Constenla M, Díaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascón P, Guillem V.

J Pain Res. 2019 Jul 29;12:2349-2358. doi: 10.2147/JPR.S203903. eCollection 2019.

5.

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.

Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E.

Br J Cancer. 2019 Aug;121(5):378-383. doi: 10.1038/s41416-019-0537-z. Epub 2019 Jul 31.

6.

Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing.

Lorca V, Rueda D, Martín-Morales L, Fernández-Aceñero MJ, Grolleman J, Poves C, Llovet P, Tapial S, García-Barberán V, Sanz J, Pérez-Segura P, de Voer RM, Díaz-Rubio E, de la Hoya M, Caldés T, Garre P.

Sci Rep. 2019 Jul 8;9(1):9814. doi: 10.1038/s41598-019-46403-5.

7.

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.

Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E.

Sci Rep. 2019 Jun 20;9(1):8976. doi: 10.1038/s41598-019-45616-y.

8.

Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.

Lopez-Perolio I, Leman R, Behar R, Lattimore V, Pearson JF, Castéra L, Martins A, Vaur D, Goardon N, Davy G, Garre P, García-Barberán V, Llovet P, Pérez-Segura P, Díaz-Rubio E, Caldés T, Hruska KS, Hsuan V, Wu S, Pesaran T, Karam R, Vallon-Christersson J, Borg A; kConFab Investigators, Valenzuela-Palomo A, Velasco EA, Southey M, Vreeswijk MPG, Devilee P, Kvist A, Spurdle AB, Walker LC, Krieger S, de la Hoya M.

J Med Genet. 2019 Jul;56(7):453-460. doi: 10.1136/jmedgenet-2018-105834. Epub 2019 Mar 19.

9.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
10.

Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.

Cabezas-Camarero S, de la Orden García V, García-Barberán V, Mediero-Valeros B, Subhi-Issa AI, Llovet García P, Bando-Polaino I, Merino Menéndez S, Pérez-Segura P, Díaz-Rubio E.

Oncologist. 2019 Mar;24(3):293-300. doi: 10.1634/theoncologist.2018-0387. Epub 2019 Jan 2.

11.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A.

Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

12.

Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

Casado A, Callata HR, Manzano A, Marquina G, Alonso T, Gajate P, Sotelo M, Cabezas S, Fernández C, Díaz-Rubio E.

Future Oncol. 2019 Jan;15(3):271-280. doi: 10.2217/fon-2018-0554. Epub 2018 Nov 22.

13.

The burden of cancer in Spain.

Badía X, Tort M, Manganelli AG, Camps C, Díaz-Rubio E.

Clin Transl Oncol. 2019 Jun;21(6):729-734. doi: 10.1007/s12094-018-1972-7. Epub 2018 Nov 9.

PMID:
30414063
14.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.

Eur J Cancer. 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27.

15.

Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition.

Martin-Morales L, Rofes P, Diaz-Rubio E, Llovet P, Lorca V, Bando I, Perez-Segura P, de la Hoya M, Garre P, Garcia-Barberan V, Caldes T.

PLoS One. 2018 Sep 26;13(9):e0203885. doi: 10.1371/journal.pone.0203885. eCollection 2018.

16.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, Safont MJ, Alcaide J, Gómez A, López R, Manzano JL, Méndez Ureña M, Sastre J, Rivera F, Grávalos C, García T, Martín-Valadés JI, Falcó E, Navalón M, González Flores E, Ma García Tapiador A, Ma López Muñoz A, Barrajón E, Reboredo M, García Teijido P, Viudez A, Cárdenas N, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2018 Sep;101:263-272. doi: 10.1016/j.ejca.2018.06.024. Epub 2018 Jul 24.

PMID:
30054049
17.

Hyperprogression as a distinct outcome after immunotherapy.

Fuentes-Antrás J, Provencio M, Díaz-Rubio E.

Cancer Treat Rev. 2018 Nov;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. Epub 2018 Jul 18. Review.

PMID:
30053725
18.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
19.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
20.

Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients.

Sánchez-Lorencio MI, Saenz L, Ramirez P, Villalba-López F, de la Orden V, Mediero-Valeros B, Revilla Nuin B, Gonzalez MR, Cascales-Campos PA, Ferreras-Martínez D, Noguera-Velasco JA, Díaz-Rubio E, Parrilla P.

Transplant Proc. 2018 Mar;50(2):623-627. doi: 10.1016/j.transproceed.2017.11.061.

PMID:
29579870
21.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

22.

SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α.

Mira E, Carmona-Rodríguez L, Pérez-Villamil B, Casas J, Fernández-Aceñero MJ, Martínez-Rey D, Martín-González P, Heras-Murillo I, Paz-Cabezas M, Tardáguila M, Oury TD, Martín-Puig S, Lacalle RA, Fabriás G, Díaz-Rubio E, Mañes S.

Nat Commun. 2018 Feb 8;9(1):575. doi: 10.1038/s41467-018-03079-1.

23.

Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M.

Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30.

PMID:
29353165
24.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

25.

Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome.

Lorca V, Rueda D, Martín-Morales L, Poves C, Fernández-Aceñero MJ, Ruiz-Ponte C, Llovet P, Marrupe D, García-Barberán V, García-Paredes B, Pérez-Segura P, de la Hoya M, Díaz-Rubio E, Caldés T, Garre P.

PLoS One. 2017 Nov 2;12(11):e0187312. doi: 10.1371/journal.pone.0187312. eCollection 2017.

26.

Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.

López López R, Camps Herrero C, Khosravi-Shahi P, Guillem Porta V, Carrato Mena A, Garcia-Foncillas J, Cruz Hernández JJ, Gascón Vilaplana P, Antón Torres A, Diaz-Rubio E, Feyjoo Saus M, Aranda Aguilar E.

Clin Transl Oncol. 2018 May;20(5):613-618. doi: 10.1007/s12094-017-1756-5. Epub 2017 Oct 3.

PMID:
28975575
27.

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.

García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, Vivancos A.

Ann Oncol. 2017 Dec 1;28(12):2943-2949. doi: 10.1093/annonc/mdx501. Review.

28.

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.

29.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

30.

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.

García-Saenz JA, Ayllón P, Laig M, Acosta-Eyzaguirre D, García-Esquinas M, Montes M, Sanz J, Barquín M, Moreno F, Garcia-Barberan V, Díaz-Rubio E, Caldes T, Romero A.

BMC Cancer. 2017 Mar 22;17(1):210. doi: 10.1186/s12885-017-3185-9.

31.

Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation.

Ramirez P, Sáenz L, Cascales-Campos PA, González Sánchez MR, Llàcer-Millán E, Sánchez-Lorencio MI, Díaz-Rubio E, De La Orden V, Mediero-Valeros B, Navarro JL, Revilla Nuin B, Baroja-Mazo A, Noguera-Velasco JA, Sánchez BF, de la Peña J, Pons-Miñano JA, Sánchez-Bueno F, Robles-Campos R, Parrilla P.

Transplant Proc. 2016 Nov;48(9):2962-2965. doi: 10.1016/j.transproceed.2016.07.035.

PMID:
27932119
32.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group.

Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12.

33.

European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish.

Guillem V, Camps C, Carrato A, Díaz-Rubio E, Gascón P.

Clin Transl Oncol. 2017 Mar;19(3):288-290. doi: 10.1007/s12094-016-1545-6. Epub 2016 Sep 7.

PMID:
27604422
34.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

35.

Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique.

Camps C, Albanell J, Antón A, Aranda E, Carrato A, Cassinello J, Castellano D, Cruz JJ, Garrido P, Guillem V, Grávalos C, López G, Llorente C, Lorenzo A, Lluch A, Ignacio E, Díaz-Rubio E.

J Natl Compr Canc Netw. 2016 May;14(5):553-8.

PMID:
27160233
36.

C8-T1 Radiculopathy Due to an Intradural Extramedullary Metastasis of a Pancreatic Neuroendocrine Tumor: Case Report and Review of the Literature.

Cabezas-Camarero S, Sastre J, Polidura MC, Gómez-Ruíz MN, Subhi-Issa I, Alonso Lera P, Paredes BG, Díaz-Rubio E.

Pancreas. 2016 May-Jun;45(5):772-9. doi: 10.1097/MPA.0000000000000515. Review.

PMID:
27077714
37.

Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation.

Sánchez-Lorencio MI, Ramirez P, Saenz L, Martínez Sánchez MV, De La Orden V, Mediero-Valeros B, Veganzones-De-Castro S, Baroja-Mazo A, Revilla Nuin B, Gonzalez MR, Cascales-Campos PA, Noguera-Velasco JA, Minguela A, Díaz-Rubio E, Pons JA, Parrilla P.

Transplant Proc. 2015 Nov;47(9):2639-42. doi: 10.1016/j.transproceed.2015.10.003.

PMID:
26680058
38.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

39.

BRCA2 gene mutations and coagulation-associated biomarkers.

Perez-Segura P, Zamorano-León JJ, Acosta D, Santos-Sancho JM, Modrego J, Caldés T, de la Hoya M, Díaz-Rubio E, Díaz-Millán I, de Las Heras N, Rico Zalba LA, Lahera V, Melander O, López Farré A.

Thromb Haemost. 2016 Jan;115(2):415-23. doi: 10.1160/TH15-06-0520. Epub 2015 Oct 8.

PMID:
26446551
40.

Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.

Sastre J, Serrano JJ, Fernández C, Ramirez C, Ortega L, García-Paredes B, Corona J, Alfonso R, Córdoba S, Díaz-Rubio E.

Clin Colorectal Cancer. 2016 Jun;15(2):128-34. doi: 10.1016/j.clcc.2015.08.001. Epub 2015 Aug 24.

PMID:
26385572
41.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E.

Mol Diagn Ther. 2015 Dec;19(6):397-408. doi: 10.1007/s40291-015-0165-0.

PMID:
26341080
42.

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.

Romero A, Acosta-Eyzaguirre D, Sanz J, Moreno F, Serrano G, Díaz-Rubio E, Caldés T, Garcia-Saenz JÁ.

Transl Res. 2015 Dec;166(6):783-7. doi: 10.1016/j.trsl.2015.04.010. Epub 2015 Apr 27.

PMID:
26001593
43.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

Sastre J, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Grávalos C, Safont MJ, Martínez Villacampa M, Llovet P, Dotor E, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours TTD.

Eur J Cancer. 2015 Jul;51(11):1371-80. doi: 10.1016/j.ejca.2015.04.013. Epub 2015 May 8.

PMID:
25963019
44.

BRCA1 Alternative splicing landscape in breast tissue samples.

Romero A, García-García F, López-Perolio I, Ruiz de Garibay G, García-Sáenz JA, Garre P, Ayllón P, Benito E, Dopazo J, Díaz-Rubio E, Caldés T, de la Hoya M.

BMC Cancer. 2015 Apr 3;15:219. doi: 10.1186/s12885-015-1145-9.

45.

New challenges in kidney cancer management: integration of surgery and novel therapies.

Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL.

Curr Treat Options Oncol. 2015 Mar;16(3):337. doi: 10.1007/s11864-015-0337-5. Review.

PMID:
25782687
46.

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.

Sotelo MJ, García-Sáenz JA, Manso L, Moreno F, Ciruelos E, Callata HR, Mendiola C, Cabezas S, Ghanem I, Díaz-Rubio E.

J Cancer Res Ther. 2014 Oct-Dec;10(4):967-72. doi: 10.4103/0973-1482.138017.

47.

Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors.

Veganzones S, Maestro ML, Rafael S, de la Orden V, Vidaurreta M, Mediero B, Espantaleón M, Cerdán J, Díaz-Rubio E.

Tumour Biol. 2015 May;36(5):3853-61. doi: 10.1007/s13277-014-3027-1. Epub 2015 Jan 10.

PMID:
25576161
48.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E, García-Alfonso P, Gallego-Plazas J, Lopez C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Díaz-Rubio E.

Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15.

49.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E.

Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.

PMID:
25491381
50.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ.

J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10.

Supplemental Content

Loading ...
Support Center